Last Update:
December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
The
LOPSAQ study: 48-week analysis of a boosted double protease inhibitor
regimen containing
lopinavir/ritonavir plus saquinavir without additional
antiretroviral therapy
Staszewski S., Babacan E., Stephan C., et al
PDF
Poster
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
The ´´95% adherence rule´´ may not apply to lopinavir/ritonavir (LPV/r)
based HAART regimens
Shuter J., Sarlo J.A., Kanmaz T.J .,et al
PDF Poster
POSTER
Lopinavir concentrations do not differ between African-Americans and
Caucasians administered
once daily HIV therapy
Wohl D., Menezes P., Torres R,
et al
PDF Poster
POSTER
Economic and clinical impact of using a protease inhibitor regimen
containing atazanavir + ritonavir
vs. lopinavir/ritonavir in antiretroviral
(ARV) experienced patients: modeling the lifetime impacts of
the 48 week results from BMS AI424-045
Simpson K.N., MacKinnon III G.E.
PDF Poster
POSTER
Characterization of HIV-2 variants in response to in vitro passage with
lopinavir
Masse S., Lu X., Dekhtyar T., et al
PDF Poster
POSTER
The
steady state pharmacokinetics (PK) of lopinavir (LPV)/ritonavir (RTV)
533/133 mg bid plus nevirapine
(NVP) (200 mg bid) in adult HIV-1-infected
individuals (the NRTI sparing study)
Youle M., Else L., Cuthbertson Z., et al
PDF Poster
A two-year
randomized controlled clinical trial in antiretroviral-naïve subjects using
lopinavir/ritonavir
(LPV/r)
monotherapy after initial induction treatment compared to an efavirenz (EFV)
3-drug regimen
(Study
M03-613)
W. Cameron, B. da Silva, J. Arribas, et al
Abstract
MONARK Trial
(MONotherapy AntiRetroviral Kaletra): 48-Week Analysis of
Lopinavir/Ritonavir (LPV/r)
Monotherapy compared to LPV/r + Zidovudine/Lamivudine (AZT/3TC) in
Antiretroviral-Naïve Patients
J.-F. Delfraissy, P. Flandre, C. Delaugerre, et al
Abstract
Lopinavir/ritonavir as single-drug maintenance therapy in patients with
HIV-1 viral suppression: Forty
eight week results of a randomized, controlled, open label, clinical trial
(OK04 Study)
J. Arribas, F. Pulido, R. Delgado, et al
Abstract
A
prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing
regimens for initial treatment
of HIV-1 infection - ACTG 5142
S.A. Riddler, R. Haubrich, G. DiRienzo, et al
Abstract
The KLEAN
Study: Fosamprenavir + ritonavir (FPV/r) versus lopinavir/ritonavir (LPV/r)
in antiretroviral-naïve
(ART-Naïve) HIV-1 infected adults over 48 weeks
J. Eron, P. Yeni, J. Gathe, Jr., et al
Abstract
48-week
efficacy and safety results of simplification to single agent
lopinavir/ritonavir (LPV/r) regimen in
patients suppressed below 80 copies/mL on HAART - the KalMo study
Nunes E.P., Oliveira M.S., Almeida M.M.T.B. et al
Abstract
Effect of Lopinavir (LPV) and Atazanavir (ATV) on Proteasome Activity of
Jurkat, U937 and HEL299 cell
lines.
Tronconi E., Groettrup M., Valerio, et al
Abstract
No
gender-specific difference in lopinavir plasma-levels
Winzer R., Benesic A., Klinker H.,
Langmann P.
Abstract
Evaluation of a new elisa method for measuring lopinavir and ritonavir
plasma concentrations
Zanone Poma B., Sciandra M., et al
Abstract
Changes in lipid profile upon switching from lopinavir/rtv (LPV/r) to
atazanavir/rtv (ATZ/r) based
HAART
Guillemi S., Toulson A., Joy R, et al
Abstract
HAART simplification therapy with lopinavir/r once or twice a day in chronic
HIV infection: a pilot study
Falci D., Bay M., Marques L., et al
Abstract
There is no difference between genotypic-based or expert empiric HAART
rescue therapy with lopinavir/r:
data from a southern Brazilian cohort
Bay M., Falci D., Marques L., et al
Abstract
Lopinavir/ritonavir during the pregnancy of HIV-infected women
Sovric M., Gingelmaier A., Kaestner R., et al
Abstract
Higher incidence of lopinavir induced symptomatic bradyarrhythmia in
HIV-1-infected persons aged
50 years or older
Honda M., Tanuma J., Yazaki H., et al
Abstract
Pharmacokinetics, tolerability and therapeutic response of double boosted
protease inhibitor (PI)
antiretroviral (ARV) therapy with
lopinavir/ritonavir and atazanavir administered once (od) and twice daily
(bd)
in patients with HIV-1 infection
Bloch M., Quan D., Kaufmann G., et al
Abstract
Single agent HAART with lopinavir/r (LPV/r) in ART-naive and pre-treated
HIV-1-infected patients
Goelz J., Wolf E., Moll A., et al
Abstract
Evaluating the tolerability of lopinavir/ritonavir liquid in HIV-positive
adults switched from the soft-gel
capsule (SGC) formulation
Toy J., Harris M., da Silva J., et al
Abstract
Long-term safety and effectiveness of ritonavir (RTV), nelfinavir (NFV) and
lopinavir/ritonavir (LPV/r)
in antiretroviral (ARV) -experienced
HIV-1-infected children
Rudin C., Burri M., Shen Y., et al
Abstract
Liver toxicity of efavirenz (EFV) and lopinavir/ritonavir (LPV/r) based
regimens as first-line therapy in the
clinical practice
Perez-Elias M.J., Moreno A., Moreno S., et al
Abstract
Kaletra (lopinavir/ritonavir) on treatment of HIV-infected children
Jugulete G., Luminos M., Mardarescu M., et al
Abstract
48-week efficacy and safety results of simplification to single agent
lopinavir/ritonavir (LPV/r) regimen
in patients suppressed below 80
copies/mL on HAART - the KalMo study
Nunes E.P., Oliveira M.S., Almeida M.M.T.B., et al
Abstract
Characterization of lipid changes associated with lopinavir/ritonavir
(LPV/r) vs. efavirenz (EFV) with and
without stavudine (d4T) in HIV-infected
patients
Guest J., Rimland D., Ataher Q.
Abstract
Efficacy and safety of lopinavir/r in HIV/HCV co-infected patients. An
open-label, phase IV study
Mingrone H., Porteiro N., Loiza E.
Abstract
Low
initial trough plasma concentrations of lopinavir are associated with an
impairment of virological
response in an unselected cohort of HIV-1-infected
patients
Wateba M.N.I., Billaud E., Dially E.,
et al
Abstract
Overview of
drug interactions between brecanavir (BCV) and other HIV protease inhibitors
(PIs)
Shelton M.J., Ford S., Anderson M.T. et al
Abstract
|
KLS
Main Page